Corina promotes endometrial growth and acts as a physical barrier to prevent re-adhesion. Credit: mi_viri/Shutterstock.

Yipurun (Shanghai) Biotechnology’s Corina Intrauterine Drug-Eluting System, a drug-device-combination therapy, has received approval in China for treating moderate-to-severe intrauterine adhesions (IUA).

The system is designed for treating patients with IUA who undergo transcervical resection of adhesions (TCRA) and offers a new therapeutic option in the field of female reproductive health.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

This approval follows a randomised controlled clinical trial that demonstrated Corina’s efficacy in comparison to the standard-of-care.

IUA, which result from damage to the uterus’s endometrial basal layer, can lead to severe reproductive health issues, including infertility and recurrent miscarriage.

With an incidence rate of up to 25% in Chinese women who have undergone certain uterine procedures, the condition represents a significant health concern.

See Also:

Despite the high incidence of intrauterine adhesions and the common use of transcervical resection of adhesions as a treatment, the recurrence rate remains alarmingly high, the company said.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The approval for Corina introduces an approach to reducing this rate and improving pregnancy outcomes post-surgery.

Corina combines a non-degradable medical-grade material with estradiol, leveraging Yipurun’s proprietary technology to release the drug over a 60-day period.

This promotes endometrial growth and acts as a physical barrier to prevent re-adhesion.

The clinical trial results for Corina have shown a statistically significant reduction in intrauterine adhesion and an improvement in endometrial thickness at 60 days post-procedure, marking a significant advance in the treatment of this condition.

Yipurun is a wholly-owned subsidiary of Puyi (Shanghai) Biotechnology (Puyi Biotech).

Puyi Biotech and YPR have developed an R&D pipeline of high-end implantable therapeutics leveraging knowhow in biomedical material science and proprietary drug-eluting technology.